Loading
Lung cancer doctor who was lead author of VISION, the trial that established tepotinib for lung cancers with MET exon 14 skipping mutations.
Paul Paik is a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center. He was first author of the 2020 New England Journal of Medicine report of the VISION trial, in which the MET inhibitor tepotinib produced durable responses in MET exon 14 skipping non-small-cell lung cancer, and earlier helped characterise MET exon 14 alterations as a targetable driver. He also studies squamous-cell lung cancer.
| Title | Journal | Year |
|---|---|---|
| VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations | New England Journal of Medicine | 2020 |
Shares Memorial Sloan Kettering Cancer Center, Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.